Nektar Therapeutics Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nektar Therapeutics stock issued during period, value, new issues for the quarter ending 2018-06-30 was $790.23M.
- Nektar Therapeutics stock issued during period, value, new issues for the quarter ending 2011-12-31 was -$617.00K.
- Nektar Therapeutics stock issued during period, value, new issues for the quarter ending 2011-09-30 was $0.00.
- Nektar Therapeutics stock issued during period, value, new issues for fiscal 2018 was $790.23M.
- Nektar Therapeutics stock issued during period, value, new issues for fiscal 2016 was $189.28M.
- Nektar Therapeutics stock issued during period, value, new issues for fiscal 2014 was $116.54M.
- Nektar Therapeutics stock issued during period, value, new issues for fiscal 2011 was $219.78M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2018-12-31 | $790.23M 10-K · filed 2021-02-26 | |
| 2018-06-30 | $790.23M 10-Q · filed 2019-11-07 | |
| 2016-12-31 | $189.28M 10-K · filed 2019-03-01 | |
| 2014-12-31 | $116.54M 10-K · filed 2017-03-01 | |
| 2011-12-31 | -$617.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $219.78M 10-K · filed 2014-02-27 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |